{"filing":{"accession_number":"0002007919-26-000037","cik":"0002007919","ticker":"INBX","company_name":"Inhibrx Biosciences, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"inhibrx-20260715.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/inhibrx-20260715.htm"},"events":[{"id":18402,"run_id":16542,"accession_number":"0002007919-26-000037","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Inhibrx entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance on July 15, 2026, expanding the credit facility to $500.0 million aggregate principal and immediately funding $100.0 million in Term C Loan proceeds, with an additional $225.0 million available upon request. This represents a material creation of new direct financial obligations.","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17201,"accession_number":"0002007919-26-000037","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibrx entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance on July 15, 2026, expanding the credit facility to $500.0 million aggregate principal and immediately funding $100.0 million in Term C Loan proceeds. This represents a material creation of new direct financial obligations. While the amendment also includes warrant issuance (21,457 shares at $93.21 per share), the primary disclosed action is the debt facility expansion and funding, making debt_issuance the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:52.829393+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17202,"accession_number":"0002007919-26-000037","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibrx entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance, expanding the total facility to $500 million and immediately funding $100 million in Term C Loan proceeds, with an additional $225 million available upon request. This represents a material creation of new direct financial obligations through debt issuance, accompanied by warrant issuance (21,457 shares at $93.21 strike). The filing explicitly references Item 2.03, which governs creation of direct financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:52.829393+00:00","company_name":"","ticker":null,"filing_date":""},{"id":17204,"accession_number":"0002007919-26-000037","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Inhibrx entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance, expanding the total facility to $500.0 million and immediately funding $100.0 million as the Term C Loan, with an additional $225.0 million available upon request. This represents a material creation of new direct financial obligations. The issuance of 21,457 warrants at a strike price of $93.21 per share is incidental to the debt financing structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:52.829393+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":18403,"run_id":16542,"accession_number":"0002007919-26-000037","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"As partial consideration for the Term C Loan, Inhibrx issued 21,457 unregistered warrants to purchase common stock to Oxford Finance at a strike price of $93.21 per share under Section 4(a)(2) and Regulation D exemptions. This dilutive issuance materially affects shareholder equity and voting power.","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17203,"accession_number":"0002007919-26-000037","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibrx issued 21,457 warrants to purchase common stock to Oxford Finance as partial consideration for a $100 million Term C Loan. The warrants are unregistered securities issued under Section 4(a)(2) and Regulation D exemptions to accredited investors. This is a classic dilutive issuance tied to debt financing, materially affecting shareholder equity and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:52.829393+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17201,"accession_number":"0002007919-26-000037","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibrx entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance on July 15, 2026, expanding the credit facility to $500.0 million aggregate principal and immediately funding $100.0 million in Term C Loan proceeds. This represents a material creation of new direct financial obligations. While the amendment also includes warrant issuance (21,457 shares at $93.21 per share), the primary disclosed action is the debt facility expansion and funding, making debt_issuance the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:52.829393+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-07-16"},{"id":17202,"accession_number":"0002007919-26-000037","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibrx entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance, expanding the total facility to $500 million and immediately funding $100 million in Term C Loan proceeds, with an additional $225 million available upon request. This represents a material creation of new direct financial obligations through debt issuance, accompanied by warrant issuance (21,457 shares at $93.21 strike). The filing explicitly references Item 2.03, which governs creation of direct financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:52.829393+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-07-16"},{"id":17203,"accession_number":"0002007919-26-000037","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibrx issued 21,457 warrants to purchase common stock to Oxford Finance as partial consideration for a $100 million Term C Loan. The warrants are unregistered securities issued under Section 4(a)(2) and Regulation D exemptions to accredited investors. This is a classic dilutive issuance tied to debt financing, materially affecting shareholder equity and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:52.829393+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-07-16"},{"id":17204,"accession_number":"0002007919-26-000037","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Inhibrx entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance, expanding the total facility to $500.0 million and immediately funding $100.0 million as the Term C Loan, with an additional $225.0 million available upon request. This represents a material creation of new direct financial obligations. The issuance of 21,457 warrants at a strike price of $93.21 per share is incidental to the debt financing structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:08:52.829393+00:00","company_name":"Inhibrx Biosciences, Inc.","ticker":"INBX","filing_date":"2026-07-16"}]}